Patient-Reported Preferences in Treatments Approved in Neuroendocrine Tumors: A National Survey from the French Group of Endocrine Tumors Abstract #1591

Introduction: Patients with advanced neuroendocrine tumors (NETs) benefit from an increasing number of treatments. The patient’s preference could help physicians to choose among these options
Aim(s): Our patient-reported outcome survey aims to compare the perceived tolerance of treatments approved in NET patients
Materials and methods: Patients with advanced NETs treated by at least 3 different treatments were eligible. Patients evaluated their perceived tolerance from 1 (good) to 5 (poor) for each received treatment. Referent physician confirmed the type and ranking over time of each treatment.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr Arnaud Plante

To read results and conclusion, please login ...

Further abstracts you may be interested in

#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors
Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Msc Catharina M Korse
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting
Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Michela Del Prete
#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors
Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof. Huang-Ying Tan
Authors: Wang X, Li Y L, Shi Y F, Chen Y Y, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.